Business Development Representative - French

Metecon x Flinn: partnership for ai-powered regulatory processes. 30/03/2026 Do you have any questions about the article or would you like to find out more about its services? Metecon GmbH look forward to hearing from you! Searching country-specific safety databases, ongoing literature reviews, and audit-ready reports under the MDR and IVDR: What PMS requires today is still done manually in many companies. This ties up resources that are urgently needed elsewhere. Automation is the obvious solution, but success depends not only on choosing the right tool, but also on whether it is implemented in a regulatory-compliant manner. The partnership between Metecon and Flinn shows how the two go hand in hand. A collaboration based on shared convictions. Flinn impressed Metecon from its very first meeting: structured automation of repetitive PMS tasks, validated software, and a clear regulatory foundation. Since then, Metecon GmbH has confidently recommended Flinn to companies with precisely these needs. The professional exchange between its teams has also been intensive from the very beginning: Metecon provides user feedback from real-world projects, while Flinn keeps Metecon up to date on further developments. This reciprocity is not a byproduct of its partnership, but its very core. Why Flinn and Metecon are such a good fit. PMS has become an ongoing process with direct implications for clinical operations, risk management, and documentation, particularly under the MDR and IVDR. At the same time, the manual effort required for literature searches, database queries, and report generation is significant in many companies: data from various sources is manually consolidated, searches are repeated, and reports are laboriously prepared. This ties up resources that are lacking elsewhere. Flinn automates precisely these tasks: in a structured, reproducible manner, with traceable results. Metecon complements this technological strength with: * in-depth regulatory expertise in PMS, Clinical Affairs, and Technical Documentation, * independent consulting on the implementation and regulatory-compliant integration of the AI solution, * practical experience from client projects that directly informs the solution's implementation. This creates a comprehensive system that not only works technically but also stands up to regulatory scrutiny: AI automation + regulatory expertise = efficient, audit-ready, and scalable PMS processes Flinn and Metecon: What sets this partnership apart. Metecon operates completely vendor-neutral in this partnership, as in all other digitalization partnerships. Metecon GmbH do not receive commissions and recommend Flinn only if the solution fits a manufacturer's specific needs. At the same time, Metecon holds its own licenses and knows Flinn inside and out. This ensures a level of consulting quality grounded in experience. "Flinn addresses the areas where manufacturers lose time every day: repetitive, data-intensive tasks in PMS and clinical operations. What makes our partnership special is Metecon's deep regulatory expertise and the fact that the team consistently integrates technology and regulatory considerations." Bastian Krapinger-Rüther, CEO of Flinn "Flinn relieves teams of the data-intensive routine work that repeatedly arises in PMS processes and makes the results audit-ready. This is not a minor efficiency gain, but a structural relief that frees up capacity that manufacturers urgently need elsewhere." Alexander Fink, Managing Director of Metecon Working together for future-proof regulatory processes. Manufacturers working with Flinn and Metecon benefit from: * automated monitoring of relevant safety databases and literature, * audit-ready reports without additional manual effort, * regulatory-compliant implementation and integration into existing processes, * independent consulting that integrates technology and organizational structure. Take advantage of this opportunity. If you'd like to know how Flinn and Metecon can streamline your PMS processes: Would you like to find out how digitalising your regulatory workflows could make your work more transparent and efficient? Take a look here.

Flinn secures $20M to develop AI tools for product lifecycle management in medtech and pharma. Flinn develops AI-based software that automates regulatory and quality processes in medtech, aiming to help manufacturers manage compliance more efficiently, reduce administrative workload, and support innovation across the medical product lifecycle. Vienna-based Flinn, a provider of AI-powered software designed to automate regulatory and quality processes in medtech, has raised $20 million in additional funding. The round was led by HV Capital, with participation from US-based healthcare investor BHI - Bertelsmann Healthcare Investments, alongside continued support from existing investors Cherry Ventures, Speedinvest, and SquareOne. The funding comes as healthcare systems globally face increasing pressure from ageing populations, more complex treatment approaches, and administrative challenges that are placing strain on public healthcare budgets. As costs rise, governments face growing difficulty managing expenditure, while patients may encounter reduced access to new treatments or higher out-of-pocket costs. Medical devices and pharmaceuticals can improve efficiency through areas such as automated healthcare, advanced diagnostics, and personalised treatments. However, innovation in these sectors is shaped by strict regulatory and quality frameworks. While these requirements are essential for patient safety, they can also extend development timelines and increase the costs of bringing products to market and maintaining compliance throughout their lifecycle. As compliance demands grow, many companies face rising operational complexity in managing regulatory and quality processes. Flinn aims to address these challenges through AI-based software that automates regulatory workflows, data evaluation, and reporting, replacing manual, document-heavy processes with more scalable systems. Bastian Krapinger-Rüther, Co-founder and Co-CEO of Flinn, said regulatory and quality requirements are increasingly contributing to costs across the medical product lifecycle. Our software replaces manual, document-heavy workflows with automated systems that scale across products, markets, and regulatory regimes. This additional investment enables us to extend that infrastructure across more lifecycle stages and support manufacturers operating globally, By integrating automation into regulatory and quality functions, the platform aims to help manufacturers improve operational efficiency, shorten development timelines, and maintain compliance while supporting patient safety requirements. The approach is intended to reduce administrative burden and allow teams to focus more on product development and innovation. With the new funding, Flinn plans to expand its platform beyond existing regulatory and post-market solutions to cover earlier development stages as well as commercial processes, creating a unified compliance and quality framework across the full medical product lifecycle. The company also plans to use the funding to support international growth, including further expansion across Europe and entry into the US market. Follow the developments in the technology world. What would you like us to deliver to you?

Flinn, a Vienna-based healthtech startup, has raised €16.8 million ($20 million) in funding, according to Handelsblatt. Founded in 2022, the company develops AI-based software that automatically aggregates and processes regulatory data to help medical device manufacturers comply efficiently with EU Medical Device Regulation requirements. The funding will support the company's regulatory automation platform, which aims to streamline compliance processes for healthcare product makers.